Our Strategy for Growth

Currently, no anti-parasite vaccine is available in human medicine.  Most of those existing in the veterinary field are far to be fully satisfactory and do not meet optimal specifications.

Providing a real and strong scientific breakthrough, over the next 5-6 years, VitamFero is to develop:

• an ovine toxoplasmosis vaccine,
• a feline toxoplasmosis vaccine,
• a bovine neosporosis vaccine,
• a bovine cryptosporidiosis vaccine.

the registration and distribution of which will be the subject matter of partnering and license agreements with global pharmaceutical industry leaders. In this perspective, VitamFero is already looking for partners with whom it is anticipating co-developments.